Maxim Group Lowers TrovaGene, Inc. (TROV) to Hold
Maxim Group lowered shares of TrovaGene, Inc. (NASDAQ:TROV) from a buy rating to a hold rating in a report published on Friday, MarketBeat reports.
Separately, Cantor Fitzgerald reiterated an overweight rating on shares of TrovaGene in a research note on Tuesday, August 8th.
Shares of TrovaGene (NASDAQ:TROV) traded down $0.01 during mid-day trading on Friday, reaching $0.67. The company’s stock had a trading volume of 512,100 shares, compared to its average volume of 546,600. TrovaGene has a 1-year low of $0.61 and a 1-year high of $3.50.
TrovaGene (NASDAQ:TROV) last issued its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.02. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%. The business had revenue of $0.12 million during the quarter.
Several institutional investors have recently modified their holdings of TROV. LMR Partners LLP purchased a new position in shares of TrovaGene during the second quarter valued at about $151,000. Susquehanna International Group LLP grew its position in shares of TrovaGene by 2,781.0% during the second quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock valued at $174,000 after purchasing an additional 133,240 shares in the last quarter. KCG Holdings Inc. grew its position in shares of TrovaGene by 560.1% during the first quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock valued at $242,000 after purchasing an additional 178,440 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in shares of TrovaGene by 1,079.5% during the second quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock valued at $351,000 after purchasing an additional 254,601 shares in the last quarter. Hedge funds and other institutional investors own 9.05% of the company’s stock.
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.